Congestive heart failure Circulatory System Heart failure
Conditions
Interventions
Telmisartan (an angiotensin II blocker) or matched placebo.
Sponsors
Boehringer Ingelheim (Canada) Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adults greater than or equal to 55 years 2. With a history of symptomatic coronary artery disease, cerebrovascular disease, peripheral vascular disease, or diabetes mellitus 3. Without proteinuria 4. Who are intolerant of ACE inhibitors
Exclusion criteria
Exclusion criteria: Does not comply with the above criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Cardiovascular death 2. Non-fatal myocardial infarction 3. Non-fatal stroke 4. Hospitalisation for congestive heart failure | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Newly diagnosed congestive heart failure 2. Cardiovascular revascularisation procedures 3. Newly diagnosed diabetes 4. Cognitive decline (adjudication will be done by a special committee) 5. New onset of atrial fibrillation 6. Nephropathy | — |
Countries
Australia, Austria, Belgium, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Korea, South, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Russian Federation, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States of America
Outcome results
None listed